Nuvalent, Inc.
NUVLHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeNuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. At a $7.35B market cap, Nuvalent, Inc. ranks as a mid-cap company within healthcare. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-se.
Market Cap
$7.35B
Beta
1.15
P/E (TTM)
—
P/E (Fwd)
-22.24
EPS (TTM)
$-6.06
EPS (Fwd)
$-4.18
ROE
-41.2%
ROA
-22.5%
Cash
$1.29B
Total Debt
$0
Free CF
-$180.4M
52W Change
19.0%
Annual Financials
Cash vs Debt
Nuvalent, Inc. reports $1.29B in cash and $0 in total debt. Free cash flow is running at -$180.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -41.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NUVL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.